SCHEMBL7174847

SCHEMBL7174847

O=C(NS(=O)(=O)O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.43
CA1 P00915 17/20 0.42
CA2 P00918 17/20 0.42
MMP1 P03956 3/20 0.39
MMP2 P08253 3/20 0.39
MMP9 P14780 3/20 0.39
MMP8 P22894 3/20 0.39
MMP13 P45452 3/20 0.39
STS P08842 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30019489 0.98 THRB (0.46) THRBCA1CA2MMP1MMP2
SCHEMBL13455184 0.79 CA2 (0.55) THRBCA1CA2MMP1MMP2
SCHEMBL27241367 0.79 CA1 (0.41) THRBCA1CA2MMP1MMP2
SCHEMBL17577416 0.74 CA1 (0.36) THRBCA1CA2MMP1MMP2
SCHEMBL1618550 0.74 CA1 (0.41) THRBCA1CA2MMP1MMP2
SCHEMBL1618321 0.74 CA1 (0.43) THRBCA1CA2MMP1MMP2
SCHEMBL7182151 0.74 CA2 (0.46) CA1CA2
SCHEMBL1618140 0.72 CA1 (0.47) THRBCA1CA2MMP1MMP2
SCHEMBL10480408 0.72 CA2 (0.43) CA1CA2
SCHEMBL10480417 0.72 CA2 (0.43) CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6583130-B1 Substituted with acyl, oxycarbonyl, aminocarbonyl, sulfonyl, or aminosulfonyl; inhibit steroid sulfatase, do not exhibit any estrogenic effect and will not yield any estrogenic products on hydrolysis; treatment of estrogen-dependent tumors SCHERING AG (DE) 2003-06-24 US claimed
US-6583130-B1 Substituted with acyl, oxycarbonyl, aminocarbonyl, sulfonyl, or aminosulfonyl; inhibit steroid sulfatase, do not exhibit any estrogenic effect and will not yield any estrogenic products on hydrolysis; treatment of estrogen-dependent tumors SCHERING AG (DE) 2003-06-24 US disclosed